Skip to main
LVTX
LVTX logo

LVTX Stock Forecast & Price Target

LVTX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

LAVA Therapeutics NV is projected to significantly increase its revenue, with risk-adjusted earnings for LAVA-1266 expected to grow from $16 million in 2031 to $58 million by 2034, showing promising potential as the company advances its clinical programs. The collaborations with major pharmaceutical partners, Pfizer and Johnson & Johnson, are anticipated to provide substantial non-dilutive funding and support for LAVA's proprietary pipeline, emphasizing the strategic advantage of these partnerships. Furthermore, recent clinical data indicates that LAVA's products are safe, well-tolerated, and demonstrate early efficacy signals, which collectively bolster the positive outlook for the company's future growth and development in the immuno-oncology sector.

Bears say

LAVA Therapeutics NV has reported no revenue for the third quarter of 2024 and experienced a net loss of $0.46 per share, which exceeded the consensus estimate of a net loss of $0.35 per share. The company faces significant uncertainty regarding its sole clinical asset, LAVA-1266, which may be deprioritized due to the ongoing strategic review aimed at extending cash reserves. Additionally, a recent workforce reduction of approximately 30% highlights the company's challenges in a difficult market environment, contributing to a negative outlook on its stock.

LVTX has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LAVA Therapeutics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LAVA Therapeutics NV (LVTX) Forecast

Analysts have given LVTX a Buy based on their latest research and market trends.

According to 6 analysts, LVTX has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LAVA Therapeutics NV (LVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.